Bayer gets USFDA nod for Darolutamide, Docetaxel combo to treat metastatic hormone-sensitive prostate cancer Ruchika Sharma10 Aug 2022 3:00 PM ISTDarolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Drug-makers to add Candidiasis as adverse event in Patient Information Leaflet of anticancer drug Docetaxal: CDSCO Panel Susmita Roy5 Jun 2022 11:00 AM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has recommended that CDSCO may...
Bayer gets USFDA priority review for darolutamide plus docetaxel to treat metastatic hormone-sensitive prostate cancer Ruchika Sharma4 May 2022 12:00 PM ISTDarolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Abiraterone acetate helps with better quality of life than Docetaxel in Prostate Cancer: ASCO Medical Dialogues Editorial Team4 Jan 2022 9:00 AM ISTIn a new research done by Hannah L Rush and colleagues, it was shown that during a 2-year period, patient-reported QOL was superior for patients...
